This article is more than 5 years old. Information may no longer be current.

Lux Biosciences initiates trial of solution for treating dry eye, ocular surface disease

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

JERSEY CITY, N.J. — Lux Biosciences has started treating patients in a phase 1 study evaluating the safety and tolerability of a topical ophthalmic solution containing voclosporin for dry eye syndrome and other chronic ocular surface diseases, the company announced in a press release.

The compound, called LX214, is a crystal clear, aqueous, mixed micellar formulation containing a high concentration of voclosporin that is four times more potent than current benchmark therapies for treating dry eye. Based on preclinical data, the solution does not produce irritation and has demonstrated potential as a once-daily formulation, according to the release.

Lux Biosciences originally filed for a patent covering LX214 in 2007 and licensed the drug for ophthalmic indications from Isotechnika, the release said.